CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, is scheduled to present a corporate overview at BioCentury’s 22nd Annual Future Leaders in the Biotech Industry conference on March 20, 2015 at 4:00 p.m. EDT. The presentation will be followed by a breakout session. The meeting is being held at the Millennium Broadway Hotel & Conference Center in New York. A live webcast of the presentation will be accessible on the Events page of Enumeral’s website. It will be archived and available for replay for at least 60 days.
The following week, Cokey Nguyen, Ph.D., Enumeral's Vice President, Research and Development, will present an overview of Enumeral's programs, as well as research studies on human tumor-infiltrating lymphocyte (TIL) expression of PD-1 and TIM-3 from patient biopsy samples, in an oral presentation titled, "Physiologic Target Validation On Immune Effector Cells" at the Immune Checkpoint Inhibitors conference on March 26, 2015 at 12:40 p.m. The meeting, organized by Hanson Wade, is being held at the Boston Marriott Copley Place in Boston.
Enumeral is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. We believe we have a unique ability to extensively interrogate the human immune microenvironment for candidate selection and validation. We believe our unique capabilities enable us to measure drug effects in a patient-specific manner, providing the basis for developing best-in-class product candidates, based on a fundamental understanding of how immunotherapies work in each patient. We are building a pipeline of immunomodulators for the treatment of cancer and inflammatory diseases and leveraging the breadth of our technology through strategic collaborations. www.enumeral.com